NCT04332835

Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 92 (actual)
• Sponsor: Universidad del Rosario · Academic / Other
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

Convalescent plasma (CP) has been used in recent years as an empirical treatment strategy when there is no vaccine or treatment available for infectious diseases. In the latest viral epidemics, such as the Ebola outbreak in West Africa in 2014, the World Health Organization issued a document outlining a protocol for the use of whole blood or plasma collected from patients who have recovered from the Ebola virus disease by transfusion to empirically treat local infectious outbreaks

Detailed description

The process is based on obtaining plasma from patients recovered from COVID-19 in Colombia, and through a donation of plasma from the recovered, the subsequent transfusion of this to patients infected with coronavirus disease (COVID-19). Our group has reviewed the scientific evidence regarding the application of convalescent plasma for emergency viral outbreaks and has recommended the following protocol

Conditions

• Coronavirus
• Coronavirus Infection

Interventions

Type	Name	Description
DRUG	Plasma	Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.
DRUG	Standard Therapy	Standard therapy defined by institutional protocol.

Timeline

• Start date: 2020-08-08
• Primary completion: 2020-10-31
• Completion: 2020-11-15
• First posted: 2020-04-03
• Last updated: 2020-11-27

Locations

1 site across 1 country: Colombia